The companies aim to work on TCR-engineered T cell therapies for solid tumours. Credit: Volodymyr Hryshchenko on Unsplash.

Biopharmaceutical firm TScan Therapeutics has signed an agreement with Novartis to discover and develop therapies for the treatment of cancer.

The companies aim to work on TCR-engineered T-cell therapies for solid tumours. TScan’s platform will identify cancer antigens that could be targeted by TCR-based treatments.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

As part of the deal, TScan will find and characterise TCRs while Novartis will hold an option to licence and develop TCRs for up to three new targets.

Furthermore, Novartis will have rights of first negotiation for more targets and TCRs resulting from the alliance. TScan may develop TCRs that act on targets not licensed by Novartis.

TScan Therapeutics president and CEO David Southwell said: “As one of the only companies able to efficiently discover novel cancer antigens that can be targeted with TCR-based therapies, we are delighted to be collaborating with Novartis to develop important TCR treatments.

“We see expansive potential for our platform and this collaboration gives us the opportunity to work with Novartis to develop novel TCR therapies, while at the same time preserving our ability to develop our own proprietary pipeline in both liquid and solid tumours.”

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Under the agreement, Novartis will pay an upfront technology access fee and research funding of $30m to TScan.

TScan is also eligible for clinical, regulatory and sales milestone payments, as well as royalties on net sales for each product.

Earlier this month, Novartis entered an agreement with Aurobindo Pharma USA to terminate their deal covering the Sandoz US generic oral solids and dermatology businesses.

The deal was subject to closing conditions and the decision on termination comes after failing to secure the US Federal Trade Commission approval within timelines.